Moderna (LIM:MRNA) Other Financing : $46 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Moderna Other Financing?

Moderna's Other Financing for the three months ended in Dec. 2023 was $15 Mil.

Moderna's Other Financing for the trailing twelve months (TTM) ended in Dec. 2023 was $46 Mil.

Moderna Other Financing Historical Data

The historical data trend for Moderna's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Other Financing Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Financing

Get a 7-Day Free Trial

51.00

186.00

124.00

65.00

46.00

Moderna Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Financing	Get a 7-Day Free Trial															25.00	9.00	16.00	6.00	15.00

Moderna Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $46 Mil.

Moderna Other Financing Related Terms

Thank you for viewing the detailed overview of Moderna's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (LIM:MRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LIM:MRNA) » Definitions » Other Financing

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.